CASE AUTHOR Moshe Talpaz, MD Professor of Medicine Associate Director,   Translational Research Associate Chief, Division of   Hematology Oncology Director, Hematologic   Malignancies University of Michigan   Comprehensive Cancer   Center Ann Arbor, MI

Interactive Case Study: A Patient With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

January 2008
1 AMA PRA Category 1 Credit^™

Release date: January 28, 2008
Expiration date: January 31, 2009

Instructions for Participation

1. Read the following information before beginning the educational activity.
2. Study the educational activity.
3. Complete the CME test.
4. Answer the evaluation questions.
5. After successful completion of the CME test and evaluation, you will receive your certificate of credit online.

• The CME test and evaluation must be completed by January 31, 2009, in order for you to receive your certificate of credit.
• You will be permitted to take the online test only once.

Imatinib is the current standard of care for the first-line treatment of patients with chronic myeloid leukemia (CML). Although imatinib yields high response rates, there is a high rate of relapse, and some patients with advanced stages of the disease develop resistance to imatinib. Studies have identified mutations in the Bcr-Abl tyrosine kinase (TK) domain that are responsible for resistance to imatinib, leading to the development of newer agents that might overcome this resistance. Several novel TK inhibitors have recently gained US Food and Drug Administration approval for the treatment of imatinib-resistant or -intolerant CML.

The purpose of this activity is to update physicians on the current issues in the treatment of CML and apprise them of the current recommendations for the optimal monitoring and management of CML.

• Evaluate first-line treatment options for patients with CML in chronic phase (CP)
• Summarize the optimal testing options for monitoring response to therapy with small-molecule inhibitors of the Bcr-Abl tyrosine kinase in patients with CML in CP
• Discuss the safety and efficacy of second-generation Bcr-Abl tyrosine kinase inhibitors in patients with imatinib-resistant or -intolerant CML in CP

Physicians’ Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Moshe Talpaz, MD
Research Funding – Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation
Paid Consultant – Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation
Speaker’s Bureau – Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation

PER Editorial Staff
No relevant relationships to disclose

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is located on the title page. Please refer to the full prescribing information for each drug discussed in this newsletter for FDA-approved dosing, indications, and warnings.

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

• Microsoft Internet Explorer Downloads (Outside Source)
• Mozilla Firefox Product Page (Outside Source)

The views and opinions expressed in this activity are those of the authors and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the authors, and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2008 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Interactive Case Study: A Patient With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Physicians' Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3456
Fax: (214) 367-3304
E-mail: editor@pergrouplp.com